R&D Making babies healthier with a ‘lost bacterium’ At the World Without Disease Summit next month, Infinant Health CEO Mike Johnson will discuss his company’s unique insights into the infant microbiome.
News Ipsen charts $1.75bn course for Kartos acquisition Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.